Biotech IV Monitor

PHVS — Pharvaris N.V.

$2.4B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Pharvaris N.V., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2027.

Next readoutJune 2027in ~7 months
Upcoming readouts33 Phase 3
Market cap$2.4B

Upcoming readouts

Phase 3 Deucrictibant
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) · NCT07266805
June 2027
Recruiting
Phase 2/3 deucrictibant
Hereditary Angioedema; Hereditary Angioedema Type I · NCT05396105
June 2027
Enrolling
Phase 3 Deucrictibant
Hereditary Angioedema (HAE) · NCT06679881
December 2028
Enrolling

Companies working on similar indications

Discussion

No messages yet. If you follow PHVS, you can start the conversation.
Track PHVS in real time
See live implied volatility for PHVS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on PHVS
Contact — questions or corrections about PHVS: dukeupt@gmail.com